Financials
Financial year 2025
Worth noting
- A loss two years in a row.
- Figures corrected afterwards (2021).
Gross margin
€ -365,861
▲ 58% vs 2024
Profit
Caution€ -2 million
▲ 17% vs 2024
Debts
Low€ 3.5 million
▲ 23% vs 2024
Amyl Therapeutics from Liège, company number BE0758775372, closed financial year 2025 with a result of € -2 million after tax. For that financial year Amyl Therapeutics recorded a gross margin of € -365,861 and equity of € 3.5 million. Compared with financial year 2024, the result moved from € -2.4 million to € -2 million. The company made a loss. The company holds a healthy buffer. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on July 22, 2026.
What happened at Amyl Therapeutics?
What happened at Amyl Therapeutics in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- NOSHAQ PARTNERS SCRL stepped down as director. NBB
- Kenneth BUCKFIRE stepped down as director. NBB
- Christopher MAC NAUGHTON stepped down as director. NBB
- MERIEUX PARTICIPATIONS SAS stepped down as director. NBB
- New annual accounts for financial year 2025: loss of € 2 million. Source: NBB ↗
- NOSHAQ PARTNERS SCRL became a director. NBB
- Kenneth BUCKFIRE became a director. NBB
- Christopher MAC NAUGHTON became a director. NBB
In short
From € 999,692 loss in 2021 to € 2 million loss in 2025.
A new publication or filing at Amyl Therapeutics? We notify you, reason included.
Follow Amyl TherapeuticsNeed more data?
History
Every financial year, as far back as the National Bank goes.
Buffer
How long does the company survive without income?
Credit limit
Indicative credit limit, computed from the real figures.
Alerts
News about who you follow, reason included.
Then €29.99/mo excl. VAT, cancel monthly. No credit card to try; the AI assistant is not included, or only in a very limited form, during the trial month. Sign up now and you’ll be invited first.
Management
Behind Amyl Therapeutics are VACCIBIO CONSULTING SRL and Swissvention Partners GMBH.
Directors
According to the 2025 annual accounts
Director · represented by Pierre VANDEPAPELIERE
since 2020
Director · represented by Florent GROS
since 2020
Director · represented by Hugues WALLEMACQ
Also active at: CAUTION MUTUELLE DES METIERS ET NEGOCES, Fonderies J. Marichal Ketin et Cie, DARDENNE +174 more
since 2026 · until 2032
Kenneth BUCKFIRE
Director
since 2026 · until 2032
Christopher MAC NAUGHTON
Director
since 2026 · until 2032
MERIEUX PARTICIPATIONS SAS
Director · represented by CALENDA Valérie
since 2026 · until 2032
Establishments
Establishment units
Physical locations of this company
Boulevard de Patience et Beaujonc 3
4000 Liège
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 23 companies are registered at this address.
Hyloris Developments
€ 5.1 million revenue · 2025
ONCORADIOMICS same network
€ 2.4 million gross margin · 2025
DERMAX
€ 1.6 million revenue · 2025
Hyloris
€ 384,852 revenue · 2025
Hyloris Pharmaceuticals same network
€ 3.8 million revenue · 2025
+18 more
Website
Technologies
Hosting & Email
Email provider
Microsoft 365
Hosting
OVH, FR
DNS
OVH DNS
Domain
Domain
amyltx.com
Registered
2020-11-24
Registrar
OVH, SAS
Expires
2026-11-24
Website info
Features
Security
Details
- Company number
- 0758.775.372
- VAT number
- BE 0758.775.372
- Registered office
- Boulevard de Patience et Beaujonc 3, 4000 Liège
- Names & denominations
- Amyl Therapeutics
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 26 November 2020
- Peppol
- Active · Active since 11 Dec 2025
- Contact
- amyltx.com
- Activities · NACE
Speur- en ontwikkelingswerk op biotechnologisch gebied